Navigation Links
HealthSouth Reports Results for Third Quarter Ended September 30, 2008
Date:11/4/2008

net cash used in financing activities was due to the use of the cash proceeds from the divestitures of the Company's surgery centers, outpatient, and diagnostic divisions to reduce debt outstanding under its Credit Agreement during the second and third quarters of 2007. During the nine months ended September 30, 2008, the Company made approximately $194.3 million of net debt payments. During the nine months ended September 30, 2007, the Company made approximately $985.5 million of net debt payments. The net debt payments made during the nine months ended September 30, 2008 primarily resulted from the sale of the Company's corporate campus in March 2008 and the net proceeds from its June 2008 equity offering. Net cash used in financing activities for the nine months ended September 30, 2008 also included $30.3 million of cash that was sent on September 30, 2008 to the trustee of the Company's 10.750% Senior Subordinated Notes due 2008 for redemption of these notes on their maturity date of October 1, 2008.

HealthSouth Corporation and Subsidiaries

Supplemental Non-GAAP Disclosures

Reconciliation of Net Income to Adjusted Income (Loss) from Continuing

Operations and Adjusted Consolidated EBITDA (1)(3)

Three Months Ended September 30,

2008 Per Share(2) 2007 Per Share(2)

(In Millions, Except per Share Data)

Net income $6.6 $0.08 $287.6 $3.66

Loss (income) from

discontinued operations 2.8 0.03 (37.5) (0.48)

Income from continuing

operations 9.4 0.11 250.1 3.19

Government, class action,

and related settlements 17.1 0.20 3.9 0.05

Professional fees -

accounting, tax, and legal 4.0 0.05
'/>"/>

SOURCE HealthSouth Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine news :

1. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
2. HealthSouth Corporation Appoints New Member to Board of Directors
3. HealthSouth Announces Date of Third Quarter Earnings Conference Call
4. HealthSouth and Physicians Pay $14.9 Million to Settle Health Care Fraud Claims
5. HealthSouth Announces Final Agreement on Previously Disclosed Settlement with Federal Government
6. HealthSouth Issues Statement on Medicare Bill and 75% Rule
7. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
8. HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007
9. HealthSouth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference and the 2008 Credit Suisse Global Leveraged Finance Conference
10. HealthSouth Finalizes Sale of Corporate Campus to Daniel Corporation
11. HealthSouth Announces Date of 2008 First Quarter Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Study examines potential for injury when doctors decide benefits ... (HealthDay News) -- MRI scans can pose a serious ... U.S. Food and Drug Administration researchers exposed pacemakers to ... electrical voltage produced at the tip of the pacemaker ... patient,s heart. , The exposure to MRI magnetic pulses ...
(Date:12/15/2009)... Dec. 15 Accelify is proud to announce ... of Advisors. David will serve as Director of Development ... Accelify,s National Board of Advisors. ,, David ... District,s Board of Education in June 1995. As the ... of over 600,000 stretching from Northeast Los Angeles through ...
(Date:12/15/2009)... Mergers and acquisitions are commonplace today. ... globally or complete a product portfolio they also ... safety programs. ,, A new free, white paper ... a Hearing Conservation Program: US Airways ," details ... West led the newly formed company to enhance ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The ... Market Forecasts to 2015, Competitive Benchmarking, ... ,, http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... has released its latest research "The ...
(Date:12/15/2009)... CHICAGO, Dec. 15 Research shows a ... return on investment as building a culture of ... improved performance(1). According to a new white paper ... wellness solutions, the workplace represents an ideal setting ... and building and sustaining a corporate culture of ...
Breaking Medicine News(10 mins):Health News:Patients With Pacemakers Should Avoid MRI Scans 2Health News:Accelify Announces the Addition of David Tokofsky to its National Board of Advisors 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 3Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 4Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 23Health News:Optimizing Corporate Culture is Critical to the Success of Wellness Programs 2
... is an early or predisposing event in the pathogenesis ... research which appears online on September 23 in the ... Myelodysplastic syndrome is a heterogeneous group of diseases ... hematopoietic lineages, clonal evolution and a tendency to progress ...
... been used widely in the treatment of hypertension ... hypertension guidelines. Moreover, after myocardial infarction and in ... blockers prevents re-infarction, hospitalisation for heart failure, and ... that atenolol is not very effective in hypertension. ...
... of bleeding from solid abdominal organs has been traditionally ... which has latelybeen recognized as detrimental. // Although there ... hemorrhage, bleeding is still the direct cause of death ... ,There is a continuous search for the "magical drug" ...
... has produced two Anti-retrovirals which can be used ... Nevirapine and Zidovudine is produced by CMSI in ... two drugs were officially released by Sebastian Ouseperamppil, ... which could maintain the quality control and Research ...
... Reddy Union Minister of Information, Broadcasting and Culture, India ... public regarding the prevention and treatment of HIV infections. ... social relevance. The media could play an important role ... the different broadcasting tools such as radio, websites, SMS, ...
... study, published in the October issue of the journal ... immune system abnormalities, including reduced levels of NKT cells, ... cells in the liver regulate production of cytokines, which ... may contribute to obesity -related liver disease. ,The ...
Other Medicine News:Health News:Evidence against use of Beta blockers as first choice in the treatment of primary hypertension 2Health News:Aprotinin in the treatment of hemorrhagic shock trauma patients 2Health News:Obesity As A Contributor To Liver Disease 2
(Date:12/15/2009)... Varian Medical Systems (NYSE: VAR ... first quarter of fiscal year 2010 following the close ... The news release will be followed by a teleconference ... The news release and a link to the ... website at: www.varian.com/investor . To access the ...
(Date:12/15/2009)... Dec. 15 Vivakor, Inc. (OTC ... divisions have reported strong performance in 2009. ... and development with divisional spokes developing multiple ... Product Pipeline strategy is anchored to the ... idea inception, Vivakor,s R&D efforts target commercialization ...
(Date:12/15/2009)... -- Estill Medical Technologies, Inc., a family-owned Texas company ... Fluid Infusion Warmer , a patented medical device being ... and emergency responders to lessen the effects ... Unit of South Lake Tahoe as the first-ever recipient ... ,, CALSTAR is a California-based nonprofit emergency ...
Breaking Medicine Technology:Varian Medical Systems Schedules First Quarter FY2010 News Release and Conference Call 2Vivakor Divisions Continue to Demonstrate Independent Growth 2Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 2Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 3Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 4Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males 12882 1Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males 12882 2American Society of Medical Doctors Established to Protect the Bond Between Physicians and Patients 3B Organizing Doctors to Oppose Government Run Hea 50645 1American Society of Medical Doctors Established to Protect the Bond Between Physicians and Patients 3B Organizing Doctors to Oppose Government Run Hea 50645 2News media registration open for 20th World Diabetes Congress 50640 1
... for XIENCE V with No,Late Stent Thrombosis ... Three Years, BARCELONA, Spain, May 22, 2007 ... trial demonstrated no,additional Major Adverse Cardiac Events ... treated with either Abbott's XIENCE(TM) V,Everolimus Eluting ...
... of SEROQUEL XR--, WILMINGTON, Del., May 22, ... analyses from a large-scale,study that investigated the ... a once-daily medicine for the,treatment of schizophrenia ... annual meeting of the American Psychiatric Association,(APA). ...
Other Medicine Technology:Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 2Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 3Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9
Joseph Double Hook 10 mm wide. Designated most popular model or size....
Exceptional comfort, handling and eye health with a convenient replacement schedule. Suitable for wearers seeking the ideal combination of convenience and performance in a planned replacement soft le...
The proven daily wear spherical soft contact lens....
Acuvue2 is designed to be worn as a two-week daily wear lens (which means you take the lenses out each night). It can also be worn as a one-week extended wear lens (which means you can sleep in them)...
Medicine Products: